HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

G Halmos Selected Research

MZ 5-156

5/2001Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
7/2000Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
3/2000Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.
1/2000Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


G Halmos Research Topics

Disease

29Neoplasms (Cancer)
10/2011 - 01/2000
7Carcinoma (Carcinomatosis)
10/2001 - 03/2000
6Neoplasm Metastasis (Metastasis)
10/2001 - 06/2000
6Prostatic Neoplasms (Prostate Cancer)
11/2000 - 02/2000
5Ovarian Neoplasms (Ovarian Cancer)
10/2011 - 06/2000
5Pancreatic Neoplasms (Pancreatic Cancer)
05/2004 - 01/2000
4Breast Neoplasms (Breast Cancer)
10/2001 - 03/2000
4Ovarian Epithelial Carcinoma
05/2001 - 06/2000
3Glioblastoma (Glioblastoma Multiforme)
10/2010 - 02/2000
3Ischemia
01/2005 - 06/2000
2Brain Neoplasms (Brain Tumor)
10/2010 - 02/2000
2Noise-Induced Hearing Loss (Acoustic Trauma)
10/2001 - 06/2000
2Renal Cell Carcinoma (Grawitz Tumor)
09/2000 - 06/2000
2Adenocarcinoma
03/2000 - 02/2000
1Cysts
11/2014
1Sensorineural Hearing Loss
01/2005
1Glioma (Gliomas)
04/2002
1Ototoxicity
10/2001
1Carcinogenesis
10/2001
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
03/2001
1Necrosis
03/2001
1Colonic Neoplasms (Colon Cancer)
05/2000
1Colorectal Neoplasms (Colorectal Cancer)
05/2000
1Leukopenia
02/2000

Drug/Important Bio-Agent (IBA)

18Messenger RNA (mRNA)IBA
10/2011 - 01/2000
14Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)IBA
10/2011 - 01/2000
12Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
10/2010 - 02/2000
9BombesinIBA
05/2004 - 03/2000
9AN 204 (AN 201)IBA
09/2001 - 02/2000
8Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2004 - 03/2000
8Peptides (Polypeptides)IBA
05/2004 - 02/2000
7Insulin-Like Growth Factor I (IGF-1)IBA
05/2004 - 01/2000
7Gonadotropin-Releasing Hormone (GnRH)FDA Link
10/2001 - 02/2000
6Gastrin-Releasing PeptideIBA
05/2004 - 03/2000
6Estrogens (Estrogen)FDA Link
10/2001 - 02/2000
5Insulin-Like Growth Factor II (Somatomedin A)IBA
05/2004 - 01/2000
5LigandsIBA
10/2001 - 02/2000
5Somatostatin Receptors (Somatostatin Receptor)IBA
10/2001 - 06/2000
5AN 238IBA
09/2001 - 02/2000
4somatotropin releasing hormone receptorIBA
10/2011 - 09/2000
4Doxorubicin (Adriamycin)FDA LinkGeneric
10/2010 - 02/2000
4vapreotideIBA
10/2010 - 07/2000
4Insulin-Like PeptidesIBA
05/2004 - 01/2000
4JV 1-36IBA
10/2001 - 03/2000
4MZ 5-156IBA
05/2001 - 01/2000
3Dopamine (Intropin)FDA LinkGeneric
01/2005 - 06/2000
3Epidermal Growth Factor (EGF)IBA
05/2004 - 03/2000
3Bombesin Receptors (Bombesin Receptor)IBA
04/2002 - 03/2000
3JV 1-38IBA
10/2001 - 07/2000
3RC 121IBA
09/2001 - 02/2000
3RNA (Ribonucleic Acid)IBA
05/2001 - 02/2000
3AN 207IBA
01/2001 - 02/2000
3AndrogensIBA
11/2000 - 07/2000
3bombesin receptor subtype 3IBA
11/2000 - 03/2000
3Membrane Proteins (Integral Membrane Proteins)IBA
09/2000 - 02/2000
3Hormones (Hormone)IBA
08/2000 - 02/2000
2AN 215IBA
04/2002 - 11/2000
2Glutamic Acid (Glutamate)FDA Link
10/2001 - 06/2000
2Carboxylic Ester HydrolasesIBA
09/2001 - 11/2000
2LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
01/2001 - 02/2000
2Radioisotopes (Radionuclides)IBA
10/2000 - 07/2000
2Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA
09/2000 - 06/2000
2Proteins (Proteins, Gene)FDA Link
09/2000 - 02/2000
2Hca(6)-Leu(13)-psi(CH2N)-Tac(14)- bombesin(6-14)IBA
07/2000 - 03/2000
2ErbB Receptors (EGF Receptor)IBA
07/2000 - 03/2000
1PhAcTyr(1)- Arg(2)- P(H)e(4- CL)(6)- Ala(8)- Tyr(Me)(10)- His(11)- Abu(15)- His(20)- Nle(27)- Arg(28)- HLCr(29)- GHRH(1-29)NH2IBA
10/2011
1MZ-J-7-118IBA
10/2011
1(N-acetyl-tyr1,D-arg2)fragment 1-29 amideIBA
10/2011
1Oxygen (Dioxygen)IBA
01/2005
1Glucose (Dextrose)FDA LinkGeneric
01/2005
1AutoreceptorsIBA
01/2005
1GastrinsIBA
05/2004
1Peptide Receptors (Peptide Receptor)IBA
05/2004
1AminoglycosidesIBA
10/2001
1Hypothalamic HormonesIBA
10/2001
1Cytotoxins (Cytolysins)IBA
01/2001
1EstersIBA
11/2000
1Androgen Antagonists (Antiandrogens)IBA
10/2000
1Delayed-Action PreparationsIBA
10/2000
1Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA
09/2000
1cetrorelix (Cetrotide)FDA Link
08/2000
1NeuropeptidesIBA
07/2000
1Capsules (Microcapsules)IBA
06/2000
1Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)- bombesin (6-14)IBA
03/2000
1Testosterone (Sustanon)FDA Link
02/2000
1Goserelin (Zoladex)FDA Link
02/2000
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
02/2000
1nucleolar organizer region associated proteinsIBA
01/2000
1MZ 4-71IBA
01/2000

Therapy/Procedure

12Therapeutics
05/2004 - 01/2000
5Drug Therapy (Chemotherapy)
04/2002 - 02/2000
4Injections
03/2001 - 02/2000
3Aftercare (After-Treatment)
11/2000 - 02/2000
2Prostatectomy (Retropubic Prostatectomy)
07/2000 - 02/2000
1Cystectomy
11/2014
1Ovariectomy (Oophorectomy)
11/2014
1Subcutaneous Injections
10/2011